Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Voltaren Emulgel becomes non-prescription in Canada

This article was originally published in Scrip

Executive Summary

Novartis's Voltaren Emulgel (diclofenac diethylamine 1.16%) has become the first topical pain reliever containing diclofenac to be available without prescription in Canada. It will be available without prescription throughout Canada, although in Quebec, it will remain behind the counter; in British Columbia, it remains on prescription pending a standard review for OTC status. Research has found that 57% of Canadians experience pain every week, with two thirds of this in the back, neck, shoulder or joints, Novartis says.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC030758

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel